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Abstract
Background: The pathogenesis of necrosis of the femoral head (NFH) remains elusive. Limited studies were
conducted to investigate the molecular mechanism of hip articular cartilage damage in NFH. We conducted
genome-wide gene expression profiling of hip articular cartilage with NFH.
Methods: Hip articular cartilage specimens were collected from 18 NFH patients and 18 healthy controls. Gene
expression profiling of NFH articular cartilage was carried out by Agilent Human 4x44K Gene Expression Microarray
chip. Differently expressed genes were identified using the significance analysis of microarrays (SAM) software. Gene
Ontology (GO) enrichment analysis of differently expressed genes was performed using the Database for
Annotation, Visualization and Integrated Discovery (DAVID). Significantly differently expressed genes in the
microarray experiment were selected for quantitative real-time PCR (qRT-PCR) and immunohistochemical validation.
Results: SAM identified 27 differently expressed genes in NFH articular cartilage, functionally involved in extracellular
matrix, cytokines, growth factors, cell cycle and apoptosis. The expression patterns of the nine validation genes in qRT-
PCR were consistent with that in proteinaceous extracellular matrix (false discovery rate (FDR) = 3.22 × 10-5), extracellular
matrix (FDR = 5.78 × 10-5), extracellular region part (FDR = 1.28 × 10-4), collagen (FDR = 3.22 × 10-4), extracellular region
(FDR = 4.78 × 10-4) and platelet-derived growth factor binding (FDR = 5.23 × 10-4).
Conclusions: This study identified a set of differently expressed genes, implicated in articular cartilage damage in NFH.
Our study results may provide novel insight into the pathogenesis and rationale of therapies for NFH.
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Background
Necrosis of the femoral head (NFH) is a debilitating dis-
ease, mainly affecting young adults aged between 35 and
55 years [1]. NFH leads to rapid destruction and dys-
function of the hip joints. About 65–70 % of patients
with advanced NFH need total hip replacement [2, 3].
The etiology and pathogenesis of NFH remains elusive,
and there is a lack of effective approaches to the preven-
tion and early treatment of NFH.
In the early stages NFH is mainly characterized by the
death of osteocytes and bone marrow cells [1, 4]. The rep-
arative reaction of necrotic bone is then initiated. During
the repair process the imbalance between osteoclast-
mediated bone resorption and osteoblast-mediated bone
reformation results in structural damage and collapse of
the femoral head. Because osteonecrosis is the representa-
tive pathological change in NFH, most studies of NFH
have focused on the mechanism of damage to the bone
and the bone marrow in the femoral head.
There is significant destruction of the hip articular car-
tilage during the development of NFH [5, 6]. Degeneration
and cracking of the hip articular cartilage increases the in-
stability of hip and accelerates the development of NFH
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[5, 6]. Prevention and early treatment of hip articular car-
tilage damage has the potential to slow the development
of NFH and relieve hip dysfunction. However, few studies
have been conducted to investigate the molecular mech-
anism of hip articular cartilage damage in NFH. To the
best of our knowledge, to date no gene expression profil-
ing of hip articular cartilage has been conducted in NFH,
limiting our efforts to clarify the pathogenesis of NFH.
In this study, we conducted genome-wide gene expres-
sion profiling of hip articular cartilage in four patients
with NFH and four healthy controls. A set of genes differ-
ently expressed in hip articular cartilage were identified
for NFH. Quantitative real-time PCR (qRT-PCR) was con-
ducted to validate the gene expression profiling results
using an independent sample of eight patients with NFH
and eight healthy controls. Our results provide novel clues
for understanding the molecular mechanism of NFH.
Methods
Ethics statement
This study was approved by the Institutional Review
Board of Xi’an Jiaotong University. Written informed
consent was obtained from all subjects.
Articular cartilage specimens
Hip articular cartilage specimens were collected from
18 patients with non-traumatic NFH and 18 healthy
control subjects at the Second Affiliated Hospital of
Xi’an Jiaotong University. All study subjects were
Chinese Han. The NFH patients and control subjects
were diagnosed according to clinical manifestations
and radiography of the hip assessed by at least two
NFH experts [7, 8]. NFH articular cartilage was col-
lected from patients with NFH classified by the the
Ficat system as grade III, who were undergoing total
hip replacement [7]. Articular cartilage was also ob-
tained from subjects without NFH, who were undergo-
ing total hip replacement within 24 hours of traumatic
femoral neck fracture. All cartilage specimens were
collected from the antero-superior portions of the fem-
oral head, where the cartilage had collapsed (Fig. 1).
Articular cartilage was only used in this study if it had
an intact gross appearance and was graded below
histological grade 2 [9, 10]. Clinical data for each par-
ticipant was recorded by doctor-administered ques-
tionnaire, including self-reported ethnicity, lifestyle
characteristics, health status, and family and medical
history. Subjects were excluded if they were identified
by assessment of clinical manifestations and radiologic
imaging of the hip as having osteoarthritis, rheumatoid
arthritis, or other hip disorders. Four, eight, and six
NFH-control pairs, matched for age and sex, were used
for microarray, qRT-PCR and immunohistochemical
analysis, respectively (Table 1).
Fig. 1 Images of femoral heads from patients (male, 51 years of age) with necrosis of the femoral head (NFH) (a, b) and healthy controls (male,
53 years of age) (c, d) in the microarray experiment. Blue boxes denote the regions used for collection of specimens from the femoral head
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RNA preparation
The obtained cartilage specimens were rapidly dissected and
frozen in liquid nitrogen, and subsequently stored at –80 °C
until RNA extraction. Frozen cartilage samples were first
rapidly ground in liquid nitrogen using a freezer mill. Total
RNA were then isolated from cartilage samples using the
Agilent Total RNA Isolation Mini kit (Agilent Technologies,
Santa Clara, CA, USA) following the manufacturer’s recom-
mended protocol. The integrity of isolated total RNA was
evaluated with 1 % agarose gel electrophoresis. The concen-
tration of isolated total RNA was determined by Agilent ND-
1000 (Agilent Technologies) (Additional file 3: Table S1).
Microarray hybridization
Total RNA was translated into complementary RNA
(cRNA) and labeled with Cy3 using the Agilent Quick
Amp Labeling kit (Agilent Technologies). Following the
Agilent One-Color Microarray-Based Gene Expression
Analysis protocol (Agilent Technology), the labeled
cRNA was purified using RNeasy Mini Kit (Qiagen,
Germantown, MD, USA)). The concentration and specific
activity of labeled cRNA were measured by Agilent ND-
1000: 1 μg of labeled cRNA was mixed with hybridization
buffer and hybridized to the Agilent Human 4x44K
Gene Expression Microarray (v2, Agilent Technologies).
Hybridization signals were recorded using the Agilent
microarray scanner (G2505C), and analyzed by Feature
Extraction v11.0 and Agilent GeneSpring GX v12.1 soft-
ware (Agilent Technologies). The quality of fluorescent
spots was evaluated, and the fluorescent spots failing to
pass the quality control procedures were excluded for
further analysis. Linear and locally weighted scatterplot
smoothing (LOWESS) normalization were conducted.
The microarray data have been deposited in the Gene
Expression Omnibus database [GEO: GSE74089].
Identification of differently expressed genes
Differently expressed genes were identified using the Sig-
nificance Analysis of Microarrays (SAM) software, Excel
plug-in version 4.01 (http://statweb.stanford.edu/~tibs/
SAM/) [11]. To ensure the accuracy of microarray data
analysis, the genes presenting both fold changes >3.0 and
false discovery rate (FDR) <0.01 were considered as being
significantly differentially expressed. The FDR values were
calculated by the permutation-based analysis algorithm of
SAM [11].
Gene Ontology enrichment analysis
Gene Ontology (GO) enrichment analysis of differently
expressed genes was performed using the functional
annotation tool Database for Annotation, Visualization
and Integrated Discovery (DAVID) 6.7 (http://david.abcc.
ncifcrf.gov/home.jsp) [12]. GO enrichment analysis can in-
tegrate the information about disease-related genes and
known functional relationships of multiple genes, and can
help identify disease-relevant gene sets with known bio-
logical functions. In this study significant GO terms were
identified at a FDR <0.01.
Quantitative real-time PCR
qRT-PCR was conducted to validate the accuracy of
microarray data using an independent sample of eight pa-
tients with NFH and eight healthy controls (Table 1).
Based on gene function and results from previous study of
joint diseases, nine cartilage development and damage-
related differently expressed genes in the microarray ex-
periment were selected for qRT-PCR validation, including
ANGPTL4, ASPN, COL1A1, COL3A1, CRTAC1, OGN,
P4HA2, SPP1 and VKORC1 [13–20]. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an en-
dogenous invariant control for data normalization. Total
RNA was isolated from cartilage specimens, and prepared
in the same way as used by the microarray experiment.
The isolated total RNA was converted into cDNA using
SuperScript III Reverse Transcriptase (Invitrogen, Carls-
bad, CA, USA). The ABI Gene Amp PCR System 9700
(Applied Biosystems) was used for cDNA amplification
and detection following the manufacturer’s recommended
protocol. The expression levels of the nine genes were
normalized to the amount of GAPDH. Relative fold
changes of genes were calculated using the comparative
cycle threshold (Ct) equation (2-△△Ct): t tests were con-
ducted to assess the significance of gene expression differ-
ences between articular cartilage in NFH and healthy
articular cartilage.
Immunohistochemical analysis
Hip cartilage specimens were collected from six patients
with NFH (three male and three female, age 53.2 ±
5.1 years) and 6 healthy control subjects (three male and
Table 1 Characteristics of study subjects
NFH Control
Age (years) Sex Age (years) Sex
Microarray 42 Male 45 Male
41 Male 42 Male
51 Male 53 Male
47 Female 47 Female
qRT-PCR 42 Male 42 Male
42 Male 54 Male
43 Male 57 Male
47 Male 61 Male
47 Male 64 Male
48 Female 60 Female
54 Female 61 Female
57 Female 63 Female
NFH necrosis of the femoral head, qRT-PCR quantitative real-time PCR
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three female, age 59.2 ± 4.3 years). The paraformaldehyde-
fixed cartilage tissues from patients with NFH and control
subjects were rinsed with phosphate-buffered saline (PBS),
decalcified and embedded in paraffin. Paraffin-embedded
cartilage tissues were sectioned (approximately 5–8 μm
thick), and placed on glass slides. For histochemical ana-
lysis the cartilage tissue slides were dewaxed in xylene, hy-
drated with graded ethanol, and stained respectively by
hematoxylin and eosin (H&E), toluidine blue (TU) and
Safranin O (SO) (Additional file 2: Figure S1). For immu-
nohistochemical analysis, the dewaxed and hydrated car-
tilage sections were treated with 3 % hydrogen peroxide
solution for 10 minutes, rinsed with PBS, and incubated
with P4HA2, SPP1 and CRTAC1 antibody (1:50 dilution,
Abcam plc, Cambridge, MA, USA) at 4 °C overnight.
After washing with PBS, the cartilage sections were incu-
bated with secondary antibody (ZHONGSHAN Golden
Bridge Biotechnology, Beijing, China) at 37 °C for 15 mi-
nutes, exposed to streptavidin-horseradish peroxidase at
37 °C for 15 minutes, and stained with 3,3-diaminobenzidine
(DAB). Four cartilage sections prepared from each cartilage
specimen were used for immunohistochemical analysis. In
the superficial zone, middle zone and deep zone of the cartil-
age (Additional file 3: Figure S2), the percentages of positive
chondrocytes in 1000 chondrocytes were calculated separ-
ately for each cartilage section. Finally, the mean percentage
of positive chondrocytes in the four cartilage sections was
reported for each cartilage specimen. Significant differences
in the expression of the P4HA2, SPP1 and CRTAC1 proteins
in cartilage specimens from the six patients with NFH and
the six control subjects were assessed using the t test. The
methods used for the negative control groups were the same
as described previously, except that the P4HA2, SPP1 and
CRTAC1 antibodies were replaced by PBS.
Results
Differently expressed genes in articular cartilage from
patients with NFH
SAM identified 24 genes that were significantly upregulated
(FDR <0.01) in articular cartilage from patients with NFH
(Table 2). The biological function of the 24 upregulated
genes mainly includes extracellular matrix (11 genes), cyto-
kines (3 genes), growth factors (2 genes), cell cycle (2 genes)
and apoptosis (1 gene). The average gene expression ratio
of the 24 upregulated genes was 16.77. Additionally, SAM
identified three significantly downregulated genes in articu-
lar cartilage from patients with NFH, including TMEM171
(FDR = 5.61 × 10-5),MDK (FDR = 4.38 × 10-4) and VKORC1
(FDR = 4.02 × 10-3). The average gene expression ratio of
the three downregulated genes was 0.42.
GO enrichment analysis
GO enrichment analysis was performed to investigate
the molecular mechanism of differently expressed genes
involved in damage to the articular cartilage in NFH. We
detected six GO terms significantly enriched in the differ-
ently expressed genes in articular cartilage from patients
withg NFH (Table 3). They are proteinaceous extracellular
matrix (FDR = 3.22 × 10 -5), extracellular matrix (FDR =
3.22 × 10-5), extracellular region part (FDR = 1.28 × 10-4),
collagen (FDR = 3.22 × 10-4), extracellular region (FDR =
4.78 × 10-4) and platelet-derived growth factor binding
(FDR = 5.23 × 10-4).
qRT-PCR validation
Nine significantly differently expressed genes in the micro-
array experiment were selected for qRT-PCR using an inde-
pendent sample of eight patients with NFH and eight
healthy controls (Fig. 2). The expression patterns of the
nine validation genes in qRT-PCR were consistent with that
in the microarray experiment, including ANGPTL4 (ratio =
4.89, P = 0.05), ASPN (ratio = 6.69, P value = 3.90 × 10-5),
Table 2 Differently expressed genes in articular cartilage from
patients with necrosis of the femoral head
Gene Genbank ID Function Ratio
COL5A1 NM_000093 Extracellular matrix 17.32 ± 4.95
CRTAC1 NM_018058 Extracellular matrix 22.67 ± 3.19
CRLF1 NM_004750 Cytokines 62.28 ± 6.61
COL6A3 NM_004369 Extracellular matrix 12.80 ± 3.25
COL3A1 NM_000090 Extracellular matrix 13.56 ± 4.24
OGN NM_033014 Extracellular matrix 10.78 ± 3.63
MT1F NM_005949 Metallothionein 6.08 ± 0.78
ANGPTL4 NM_139314 Growth factor 26.83 ± 2.65
IGFBP7 NM_001553 Growth factor 22.89 ± 6.02
COL6A1 NM_001848 Extracellular matrix 8.73 ± 2.91
CRIP1 NM_001311 Cell cycle 7.79 ± 1.88
SPP1 NM_001040058 Extracellular matrix 17.61 ± 4.10
ASPN NM_017680 Extracellular matrix 22.15 ± 5.28
MXRA7 NM_001008529 Extracellular matrix 7.94 ± 2.21
NFIL3 NM_005384 Transcription 11.05 ± 1.92
MINOS1-NBL1 NM_001204088 Miscellaneous 5.76 ± 1.57
METRNL NM_001004431 Miscellaneous 11.77 ± 3.40
P4HA2 NM_004199 Extracellular matrix 6.96 ± 1.47
COL1A1 NM_000088 Extracellular matrix 51.81 ± 15.49
TSC22D3 NM_004089 Cytokines 7.39 ± 1.92
ID2 NM_002166 Cell cycle 20.62 ± 5.78
PRG4 NM_005807 Cytokines 13.87 ± 3.72
CD55 NM_000574 Apoptosis 6.53 ± 1.52
STEAP1 NM_012449 Transmembrane protein 7.31 ± 2.21
TMEM171 NM_173490 Miscellaneous 0.34 ± 0.05
MDK NM_001012334 Cytokines 0.47 ± 0.02
VKORC1 AK125618 Miscellaneous 0.44 ± 0.09
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COL1A1 (ratio = 17.43, P value = 0.01), COL3A1 (ratio =
5.33, P value = 0.02), CRTAC1 (ratio = 5.08, P value =
4.24 × 10-3), OGN (ratio = 5.99, P value = 9.14 × 10-4),
P4HA2 (ratio = 3.12, P value = 1.30 × 10-5), SPP1 (ratio =
3.20, P value = 2.14 × 10-3), and VKORC1 (ratio = 0.56,
P value = 1.76 × 10-3).
Immunohistochemical analysis
Immunohistochemical experiments were performed to
evaluate the expression levels of the P4HA2, SPP1 and
CRTAC1 proteins in NFH and normal cartilage. As
shown in Fig. 3, expression of the P4HA2, SPP1 and
CRTAC1 proteins in the superficial zone, middle zone,
and deep zone of cartilage from patients with NFH was sig-
nificantly higher than in normal hip cartilage (all P values
<0.05). Additionally, we also observed decreased expression
levels of the P4HA2, SPP1 and CRTAC1 proteins in the
superficial zone, and middle zone to deep zone of cartilage
from both patients with NFH and normal controls.
Discussion
Previous studies have implicated degeneration and crack-
ing of hip articular cartilage in the development of NFH
[5, 6]. We compared the gene expression profiles of
articular cartilage from patients with NFH in articular
cartilage from subjects without NFH, to try and under-
stand the mechanism of damage to the articular cartilage
in NFH. We identified 24 upregulated genes and 3
downregulated genes in articular cartilage in NFH. The
27 differently expressed genes are functionally involved
mainly in the extracellular matrix, cytokines, growth
factors, cell cycle and apoptosis. To the best of our
knowledge, this is the first gene expression profile study
of articular cartilage in NFH. Our study results may pro-
vide novel insight into the pathogenesis of NFH and a
rationale for therapies.
We found that 11 extracellular-matrix-related genes
were significantly upregulated in NFH, including ASPN,
COL1A1, COL3A1, COL5A1, COL6A1, CRTAC1, MXRA7,
OGN, P4HA2, and SPP1: 4 of these are collagen genes.
COL1A1 encodes pro-alpha1 chains of type I collagen,
which is abundant in bone. COL1A1 mutations are one of
the major causes of osteogenesis imperfecta [21]. COL3A1
encodes the pro-alpha1 chains of type III collagen, which
is widely expressed in the vascular system. Loeser et al.
observed significant upregulation of COL3A1 in an osteo-
arthritis mice model [22]. COL5A1 encodes the alpha
chain of type V collagen, which is a minor component of
connective tissue. In an animal study dysfunction of
COL5A1 was found to generate an abnormal joint pheno-
type, such as joint laxity and early-onset osteoarthritis
[23]. COL6A1 encodes the alpha 1 subunit of type VI col-
lagen, which is a major structural component of microfi-
brils. COL6A1 mutations have been linked to Bethlem
myopathy with joint contractures [24]. P4HA2 encodes
procollagen-proline, 2-oxoglutarate 4-dioxygenase, which
is a key collagen synthesis enzyme [25]. P4HA2 knock-out
mice have defects in skeletal growth and development
[26]. In patients with NFH the upregulated expression of
collagen and the collagen synthesis enzyme may be ex-
plained by enhanced repairing activity in articular cartilage
defects with fibrous tissue. ASPN encodes cartilage extra-
cellular protein asporin, which is able to negatively regu-
late the chondrogenesis of articular cartilage through
Table 3 Gene Ontology enrichment analysis results for
differently expressed genes
GO term GO ID FESa FDR
Proteinaceous extracellular matrix GO:0005578 15.63 3.22 × 10-5
Extracellular matrix GO:0031012 14.50 5.78 × 10-5
Extracellular region part GO:0044421 6.95 1.28 × 10-4
Collagen GO:0005581 79.39 3.22 × 10-4
Extracellular region GO:0005576 4.15 4.78 × 10-4
Platelet-derived growth factor binding GO:0048407 224.81 5.23 × 10-4
aFold enrichment score calculated using the Database for Annotation,
Visualization and Integrated Discovery (DAVID)
Fig. 2 Results of quantitative real-time PCR. *P values <0.05; †P values <0.01; ‡P values <0.001, calculated by the t test
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blocking transforming growth factor (TGF)-beta/receptor
interaction in chondrocytes [27]. It has also been
found to be involved in damage to the articular cartil-
age in osteoarthritis and rheumatoid arthritis [13, 28–30].
SPP1 encodes secreted phosphoprotein 1 (also named
osteopontin), which is implicated in the attachment of os-
teoclasts to mineralized bone matrix. The association be-
tween SPP1 and osteoarthritis has been demonstrated
[31]. SPP1-deficient mice exhibit accelerated development
of osteoarthritis [32]. Yamamoto et al. found that SPP1
contributes to osteoclast-mediated bone resorption and
joint inflammatory responses in the mouse model of
rheumatoid arthritis [33]. OGN encodes osteoglycin,
which is capable of inducing ectopic bone formation and
regulating cardiovascular development [34, 35]. CRTAC1
encodes cartilage acidic protein 1, which is expressed in
the deep zone in articular cartilage. CRTAC1 acts as a bio-
marker for distinguishing chondrocytes from osteoblasts
and mesenchymal stem cells [17].
With respect to cytokines and growth factors, we ob-
served significant upregulation of the PRG4 and
ANGPTL4 genes in articular cartilage from patients with
NFH. PRG4 encodes proteoglycan 4, which acts as a
boundary lubricant at the surface of articular cartilage
Fig. 3 Immunohistochemistry results for P4HA2 (a), SPP1 (b) and CRTAC1 (c) proteins in cartilage from patients with necrosis of the femoral head
(NFH) and normal hip cartilage. Original magnification × 400 of the superficial zone (SZ), middle zone (MZ) and deep zone (DZ). The expression of
the P4HA2, SPP1 and CRTAC1 proteins in cartilage from patients with NFH was significantly higher than in normal hip cartilage in the SZ, MZ and
DZ: n = 6 in each group. *P values <0.05; &P values <0.001
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[36, 37]. Using transgenic mice and intra-articular
adenoviral virus gene transfer, Ruan et al. demonstrated
that PRG4 protected against the development of osteo-
arthritis in mice [38]. The ANGPTL4 gene encodes
angiopoietin-like 4, which is an important regulator of
angiogenesis [39]. Perdiguero observed that ANGPTL4-
deficient mice have impaired angiogenesis and increased
vascular leakage [40]. ANGPTL4 also simulates endothe-
lial cell growth and tubule formation, and prevents endo-
thelial cell apoptosis [39, 41]. The role of ANGPTL4 in
the dysfunctional blood supply in NFH is worthy of fur-
ther study.
Conclusion
We conducted a gene expression profile study of the ar-
ticular cartilage in NFH. We identified a set of differ-
ently expressed genes, implicated in the destruction of
articular cartilage in NFH. Further biological studies are
warranted to confirm our findings and clarify the poten-
tial mechanism of the identified genes involved in the
development of NFH.
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